Cargando…

Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, which has recently been mentioned as an independent cardiovascular risk factor. OBJECTIVES: Endocan is a novel molecule of endothelial dysfunction. We aimed to evaluate the associations of serum en...

Descripción completa

Detalles Bibliográficos
Autores principales: Erman, Hande, Beydogan, Engin, Cetin, Seher Irem, Boyuk, Banu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152978/
https://www.ncbi.nlm.nih.gov/pubmed/32317862
http://dx.doi.org/10.1155/2020/3534042
_version_ 1783521591167025152
author Erman, Hande
Beydogan, Engin
Cetin, Seher Irem
Boyuk, Banu
author_facet Erman, Hande
Beydogan, Engin
Cetin, Seher Irem
Boyuk, Banu
author_sort Erman, Hande
collection PubMed
description BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, which has recently been mentioned as an independent cardiovascular risk factor. OBJECTIVES: Endocan is a novel molecule of endothelial dysfunction. We aimed to evaluate the associations of serum endocan levels with the hepatic steatosis index (HSI), fatty liver index (FLI), and degrees of hepatosteatosis in patients with metabolic syndrome with NAFLD. Design and Setting. This cross-sectional prospective study was performed in the outpatient clinic of an internal medicine department. METHODS: The study included 40 patients with metabolic syndrome with NAFLD as noted using hepatic ultrasound and 20 healthy controls. Secondary causes of fatty liver were excluded. FLI and HSI calculations were recorded. Serum endocan level values were obtained after overnight fasting. RESULTS: Higher values of HSI and FLI were found in the NAFLD groups than in the control groups (p < 0.001). Five (12.5%) of 20 patients with liver steatosis had grade 1 liver steatosis, 15 (37.5%) patients had grade 2 liver steatosis, and 20 (50%) patients had grade 3 liver steatosis. Serum endocan levels were lower in patients with NAFLD compared with the healthy controls (146.56 ± 133.29 pg/mL vs. 433.71 ± 298.01 pg/mL, p < 0.001). ROC curve analysis suggested that the optimum endocan value cutoff point for NAFLD was 122.583 pg/mL (sensitivity: 71.79%, specificity: 90%, PPV: 93.3%, and NPV: 62.1%). CONCLUSION: Serum endocan concentrations are low in patients with NAFLD, and the optimum cutoff point is 122.583 pg/mL. HSI and FLI were higher in patients with NAFLD; however, there was no correlation with serum endocan.
format Online
Article
Text
id pubmed-7152978
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-71529782020-04-21 Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome Erman, Hande Beydogan, Engin Cetin, Seher Irem Boyuk, Banu Mediators Inflamm Research Article BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases, which has recently been mentioned as an independent cardiovascular risk factor. OBJECTIVES: Endocan is a novel molecule of endothelial dysfunction. We aimed to evaluate the associations of serum endocan levels with the hepatic steatosis index (HSI), fatty liver index (FLI), and degrees of hepatosteatosis in patients with metabolic syndrome with NAFLD. Design and Setting. This cross-sectional prospective study was performed in the outpatient clinic of an internal medicine department. METHODS: The study included 40 patients with metabolic syndrome with NAFLD as noted using hepatic ultrasound and 20 healthy controls. Secondary causes of fatty liver were excluded. FLI and HSI calculations were recorded. Serum endocan level values were obtained after overnight fasting. RESULTS: Higher values of HSI and FLI were found in the NAFLD groups than in the control groups (p < 0.001). Five (12.5%) of 20 patients with liver steatosis had grade 1 liver steatosis, 15 (37.5%) patients had grade 2 liver steatosis, and 20 (50%) patients had grade 3 liver steatosis. Serum endocan levels were lower in patients with NAFLD compared with the healthy controls (146.56 ± 133.29 pg/mL vs. 433.71 ± 298.01 pg/mL, p < 0.001). ROC curve analysis suggested that the optimum endocan value cutoff point for NAFLD was 122.583 pg/mL (sensitivity: 71.79%, specificity: 90%, PPV: 93.3%, and NPV: 62.1%). CONCLUSION: Serum endocan concentrations are low in patients with NAFLD, and the optimum cutoff point is 122.583 pg/mL. HSI and FLI were higher in patients with NAFLD; however, there was no correlation with serum endocan. Hindawi 2020-04-01 /pmc/articles/PMC7152978/ /pubmed/32317862 http://dx.doi.org/10.1155/2020/3534042 Text en Copyright © 2020 Hande Erman et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Erman, Hande
Beydogan, Engin
Cetin, Seher Irem
Boyuk, Banu
Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome
title Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome
title_full Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome
title_fullStr Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome
title_full_unstemmed Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome
title_short Endocan: A Biomarker for Hepatosteatosis in Patients with Metabolic Syndrome
title_sort endocan: a biomarker for hepatosteatosis in patients with metabolic syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152978/
https://www.ncbi.nlm.nih.gov/pubmed/32317862
http://dx.doi.org/10.1155/2020/3534042
work_keys_str_mv AT ermanhande endocanabiomarkerforhepatosteatosisinpatientswithmetabolicsyndrome
AT beydoganengin endocanabiomarkerforhepatosteatosisinpatientswithmetabolicsyndrome
AT cetinseherirem endocanabiomarkerforhepatosteatosisinpatientswithmetabolicsyndrome
AT boyukbanu endocanabiomarkerforhepatosteatosisinpatientswithmetabolicsyndrome